Certara's New Muse Invent Allows Chemistry Researchers to Design Drug Candidates That Are Synthetically Feasible

Certara's New Muse Invent Allows Chemistry Researchers to Design Drug Candidates That Are Synthetically Feasible

A breakthrough development, Muse Invent enables researchers not only to design dream molecules, but it also shows how to produce them in the lab

ST. LOUIS--()--Certara®, the leading global technology-enabled drug development and drug safety consultancy, announced today that its Muse molecular design workflow for the identification and optimization of lead drug candidates now has virtual synthetic chemistry capabilities. Known as Muse® Invent, this new product will enable researchers to create drug candidates with novel structures, scaffolds, or side-chains that meet multiple design objectives and are synthetically accessible. It will also describe the necessary synthesis pathway to create them.

"Muse has always been a popular product because it permits 'outside of the box' chemistry thinking; it allows customers to generate new chemical ideas without being limited to molecules found in existing databases and product catalogs," said Certara Chief Technology Officer Jonathan Feldmann. "But when customers became enamored with the new molecules they created in Muse, they wanted to know how to make them in the lab."

Certara responded promptly to this customer feedback and began to develop Muse Invent.

Brian Masek, a product manager at Certara, added, "Muse Invent is one of the first products to build a bridge between the traditional worlds of molecular design and synthetic chemistry. In the past, design software would suggest and score ideas, while synthetic chemistry tools would help researchers to look up reactions; Muse Invent combines both design and synthesis capabilities in a single product. It enables researchers to generate drug design ideas that satisfy all their criteria for success."

Certara will launch Muse Invent in the United States at the American Chemical Society Fall National Meeting & Exposition (booth 237) in San Francisco from Aug. 10-14. Its European launch will take place at the 20th EuroQSAR symposium in St. Petersburg, Russia from Aug. 31-Sept. 4.

About Certara

Certara is the leading technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara's solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.


Certara Contact:
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
[email protected]
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
[email protected]


Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.